Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2017

Open Access 01-12-2017 | Review

Curcumin: the spicy modulator of breast carcinogenesis

Authors: Urmila Banik, Subramani Parasuraman, Arun Kumar Adhikary, Nor Hayati Othman

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2017

Login to get access

Abstract

Worldwide breast cancer is the most common cancer in women. For many years clinicians and the researchers are examining and exploring various therapeutic modalities for breast cancer. Yet the disease has remained unconquered and the quest for cure is still going on. Present-day strategy of breast cancer therapy and prevention is either combination of a number of drugs or a drug that modulates multiple targets. In this regard natural products are now becoming significant options. Curcumin exemplifies a promising natural anticancer agent for this purpose. This review primarily underscores the modulatory effect of curcumin on the cancer hallmarks. The focus is its anticancer effect in the complex pathways of breast carcinogenesis. Curcumin modulates breast carcinogenesis through its effect on cell cycle and proliferation, apoptosis, senescence, cancer spread and angiogenesis. Largely the NFkB, PI3K/Akt/mTOR, MAPK and JAK/STAT are the key signaling pathways involved. The review also highlights the curcumin mediated modulation of tumor microenvironment, cancer immunity, breast cancer stem cells and cancer related miRNAs. Using curcumin as a therapeutic and preventive agent in breast cancer is perplexed by its diverse biological activity, much of which remains inexplicable. The information reviewed here should point toward potential scope of future curcumin research in breast cancer.
Literature
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.PubMedCrossRef
2.
3.
Sinha D, Biswas J, Sung B, Aggarwal BB, Bishayee A. Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. Curr Drug Targets. 2012;13:1799–819.PubMedCrossRef
4.
Singhal SK, Usmani N, Michiels S, Metzger-Filho O, Saini KS, Kovalchuk O, et al. Towards understanding the breast cancer epigenome: a comparison of genome-wide DNA methylation and gene expression data. Oncotarget. 2015;7:3002–17.PubMedCentral
5.
Khan SI, Aumsuwan P, Khan IA, Walker LA, Dasmahapatra AK. Epigenetic events associated with breast cancer and their prevention by dietary components targeting the epigenome. Chem Res Toxicol. 2012;25:61–73.PubMedCrossRef
6.
Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009;15:593–602.PubMedCrossRef
7.
Arslan C, Dizdar O, Altundag K. Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update. Expert Opin Pharmacother. 2014;15:1643–58.PubMedCrossRef
8.
Isakoff SJ. Triple negative breast cancer: role of specific chemotherapy agents. Cancer J Sudbury Mass. 2010;16:53–61.CrossRef
9.
Ishiba T, Nakagawa T, Sato T, Nagahara M, Oda G, Sugimoto H, et al. Efficiency of fluorodeoxyglucose positron emission tomography/computed tomography to predict prognosis in breast cancer patients received neoadjuvant chemotherapy. SpringerPlus. 2015;4:817.PubMedPubMedCentralCrossRef
10.
Shin SM, No HS, Vega RM, Fenton-Kerimian M, Maisonet O, Hitchen C, et al. Breast, chest wall, and nodal irradiation with prone set-up: results of a hypofractionated trial with a median follow-up of 35 months. Pract Radiat Oncol. 2015;
11.
Shi Z, Peddi P, Burton G, Mills G, Shi R. Effect of Postmastectomy radiation on survival of AJCC pN2/N3 breast cancer patients. Anticancer Res. 2016;36:261–9.PubMed
12.
van Rooijen JM, Stutvoet TS, Schröder CP, de Vries EGE. Immunotherapeutic options on the horizon in breast cancer treatment. Pharmacol Ther. 2015;156:90–101.PubMedCrossRef
13.
Jiang TL, Salmon SE, Liu RM. Activity of camptothecin, harringtonin, cantharidin and curcumae in the human tumor stem cell assay. Eur J Cancer Clin Oncol. 1983;19:263–70.PubMedCrossRef
14.
Kuttan R, Bhanumathy P, Nirmala K, George MC. Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett. 1985;29:197–202.PubMedCrossRef
15.
16.
Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an “old-age” disease with an “age-old” solution. Cancer Lett. 2008;267:133–64.PubMedCrossRef
17.
18.
Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, Priyadarsini IK, et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep. 2011;28:1937–55.PubMedPubMedCentralCrossRef
19.
Kurien BT, Singh A, Matsumoto H, Scofield RH. Improving the solubility and pharmacological efficacy of curcumin by heat treatment. Assay Drug Dev Technol. 2007;5:567–76.PubMedCrossRef
20.
Kurien BT, Harris VM, Quadri SMS, Coutinho-de Souza P, Cavett J, Moyer A, et al. Significantly reduced lymphadenopathy, salivary gland infiltrates and proteinuria in MRL-lpr/lpr mice treated with ultrasoluble curcumin/turmeric: increased survival with curcumin treatment. Lupus Sci Med. 2015;2:e000114.PubMedPubMedCentralCrossRef
21.
Bengmark S, Mesa MD, Gil A. Plant-derived health: the effects of turmeric and curcuminoids. Nutr Hosp. 2009;24:273–81.PubMed
22.
Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev J Clin Ther. 2009;14:141–53.
23.
Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer’s disease. Curr Alzheimer Res. 2005;2:131–6.PubMedPubMedCentralCrossRef
24.
Devassy JG, Nwachukwu ID, Jones PJH. Curcumin and cancer: barriers to obtaining a health claim. Nutr Rev. 2015;73:155–65.PubMedCrossRef
25.
Guo Y, Shu L, Zhang C, Su Z-Y, Kong A-NT. Curcumin inhibits anchorage-independent growth of HT29 human colon cancer cells by targeting epigenetic restoration of the tumor suppressor gene DLEC1. Biochem Pharmacol. 2015;94:69–78.PubMedPubMedCentralCrossRef
26.
Jin H, Qiao F, Wang Y, Xu Y, Shang Y. Curcumin inhibits cell proliferation and induces apoptosis of human non-small cell lung cancer cells through the upregulation of miR-192-5p and suppression of PI3K/Akt signaling pathway. Oncol Rep. 2015;34:2782–9.PubMed
27.
Kim H, Park J, Tak K-H, Bu SY, Kim E. Chemopreventive effects of curcumin on chemically induced mouse skin carcinogenesis in BK5.Insulin-like growth factor-1 transgenic mice. In Vitro Cell Dev Biol Anim. 2014;50:883–92.PubMedCrossRef
28.
Lee AY-L, Fan C-C, Chen Y-A, Cheng C-W, Sung Y-J, Hsu C-P, et al. Curcumin inhibits invasiveness and epithelial-Mesenchymal transition in oral Squamous cell carcinoma through reducing matrix metalloproteinase 2, 9 and modulating p53-E-Cadherin pathway. Integr Cancer Ther. 2015;14:484–90.PubMedCrossRef
29.
Liu L, Duan C, Ma Z, Xu G. Curcumin inhibited rat colorectal carcinogenesis by activating PPAR-γ: an experimental study. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015;35:471–5.PubMed
30.
Wu J, Lu W-Y, Cui L-L. Inhibitory effect of curcumin on invasion of skin squamous cell carcinoma A431 cells. Asian Pac J Cancer Prev. 2015;16:2813–8.PubMedCrossRef
31.
Wu L, Guo L, Liang Y, Liu X, Jiang L, Wang L. Curcumin suppresses stem-like traits of lung cancer cells via inhibiting the JAK2/STAT3 signaling pathway. Oncol Rep. 2015;34:3311–7.PubMed
32.
Zhao Z, Li C, Xi H, Gao Y, Xu D. Curcumin induces apoptosis in pancreatic cancer cells through the induction of forkhead box O1 and inhibition of the PI3K/Akt pathway. Mol Med Rep. 2015;12:5415–22.PubMed
33.
Beevers CS, Li F, Liu L, Huang S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer J Int Cancer. 2006;119:757–64.CrossRef
34.
Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23:363–98.PubMed
35.
Kumar U, Sharma U, Rathi G. Reversal of hypermethylation and reactivation of glutathione S-transferase pi 1 gene by curcumin in breast cancer cell line. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2017;39:1010428317692258.
36.
Liu Y, Zhou J, Hu Y, Wang J, Yuan C. Curcumin inhibits growth of human breast cancer cells through demethylation of DLC1 promoter. Mol Cell Biochem. 2017;425:47–58.PubMedCrossRef
37.
Choudhuri T, Pal S, Das T, Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem. 2005;280:20059–68.PubMedCrossRef
38.
Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996;68:67–108.PubMedCrossRef
39.
40.
Liu Q, Loo WTY, Sze SCW, Tong Y. Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation of NFkappaB, cyclinD and MMP-1 transcription. Phytomedicine Int J Phytother Phytopharm. 2009;16:916–22.CrossRef
41.
Mehta K, Pantazis P, McQueen T, Aggarwal BB. Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anti-Cancer Drugs. 1997;8:470–81.PubMedCrossRef
42.
Jiang M, Huang O, Zhang X, Xie Z, Shen A, Liu H, et al. Curcumin induces cell death and restores Tamoxifen sensitivity in the Antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. Molecules. 2013;18:701–20.PubMedCrossRef
43.
Masuelli L, Benvenuto M, Fantini M, Marzocchella L, Sacchetti P, Di Stefano E, et al. Curcumin induces apoptosis in breast cancer cell lines and delays the growth of mammary tumors in neu transgenic mice. J Biol Regul Homeost Agents. 2013;27:105–19.PubMed
44.
Zhou Q, Wang X, Liu X, Zhang H, Lu Y, Su S. Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cells in vitro and in vivo. Acta Pharmacol Sin. 2011;32:1402–10.PubMedPubMedCentralCrossRef
45.
Lee YK, Lee WS, Hwang JT, Kwon DY, Surh YJ, Park OJ. Curcumin exerts antidifferentiation effect through AMPKalpha-PPAR-gamma in 3T3-L1 adipocytes and antiproliferatory effect through AMPKalpha-COX-2 in cancer cells. J Agric Food Chem. 2009;57:305–10.PubMedCrossRef
46.
Benhaj K, Akcali KC, Ozturk M. Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncol Rep. 2006;15:701–7.PubMed
47.
Mohammadi-Yeganeh S, Paryan M, Arefian E, Vasei M, Ghanbarian H, Mahdian R, et al. MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathway. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2016;
48.
Prasad CP, Rath G, Mathur S, Bhatnagar D, Ralhan R. Potent growth suppressive activity of curcumin in human breast cancer cells: modulation of Wnt/beta-catenin signaling. Chem Biol Interact. 2009;181:263–71.PubMedCrossRef
49.
Shao Z-M, Shen Z-Z, Liu C-H, Sartippour MR, Go VL, Heber D, et al. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer J Int Cancer. 2002;98:234–40.CrossRef
50.
van Pel DM, Barrett IJ, Shimizu Y, Sajesh BV, Guppy BJ, Pfeifer T, et al. An evolutionarily conserved synthetic lethal interaction network identifies FEN1 as a broad-Spectrum target for anticancer therapeutic development. PLoS Genet. 2013;9 doi:10.​1371/​journal.​pgen.​1003254.
51.
Chen B, Zhang Y, Wang Y, Rao J, Jiang X, Xu Z. Curcumin inhibits proliferation of breast cancer cells through Nrf2-mediated down-regulation of Fen1 expression. J Steroid Biochem Mol Biol. 2014;143:11–8.PubMedCrossRef
52.
53.
Ramachandran C, Rodriguez S, Ramachandran R, Raveendran Nair PK, Fonseca H, Khatib Z, et al. Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines. Anticancer Res. 2005;25:3293–302.PubMed
54.
Lv Z-D, Liu X-P, Zhao W-J, Dong Q, Li F-N, Wang H-B, et al. Curcumin induces apoptosis in breast cancer cells and inhibits tumor growth in vitro and in vivo. Int J Clin Exp Pathol. 2014;7:2818–24.PubMedPubMedCentral
55.
Choudhuri T, Pal S, Agwarwal ML, Das T, Sa G. Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett. 2002;512:334–40.PubMedCrossRef
56.
Moghtaderi H, Sepehri H, Attari F. Combination of arabinogalactan and curcumin induces apoptosis in breast cancer cells in vitro and inhibits tumor growth via overexpression of p53 level in vivo. Biomed Pharmacother Biomedecine Pharmacother. 2017;88:582–94.CrossRef
57.
Ibrahim A, El-Meligy A, Lungu G, Fetaih H, Dessouki A, Stoica G, et al. Curcumin induces apoptosis in a murine mammary gland adenocarcinoma cell line through the mitochondrial pathway. Eur J Pharmacol. 2011;668:127–32.PubMedCrossRef
58.
Chiu T-L, Su C-C. Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-kappaBp65 expression in breast cancer MDA-MB-231 cells. Int J Mol Med. 2009;23:469–75.PubMed
59.
Patel PB, Thakkar VR, Patel JS. Cellular effect of Curcumin and Citral combination on breast cancer cells: induction of apoptosis and cell cycle arrest. J Breast Cancer. 2015;18:225–34.PubMedPubMedCentralCrossRef
60.
Yan G, Graham K, Lanza-Jacoby S. Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells. Mol Carcinog. 2013;52:404–11.PubMedCrossRef
61.
Wang K, Zhang C, Bao J, Jia X, Liang Y, Wang X, et al. Synergistic chemopreventive effects of curcumin and berberine on human breast cancer cells through induction of apoptosis and autophagic cell death. Sci Rep. 2016;6:26064.PubMedPubMedCentralCrossRef
62.
Fan H, Liang Y, Jiang B, Li X, Xun H, Sun J, et al. Curcumin inhibits intracellular fatty acid synthase and induces apoptosis in human breast cancer MDA-MB-231 cells. Oncol Rep. 2016;35:2651–6.PubMed
63.
Lee CW, Raskett CM, Prudovsky I, Altieri DC. Molecular dependence of estrogen receptor-negative breast cancer on a notch-Survivin signaling Axis. Cancer Res. 2008;68:5273–81.PubMedPubMedCentralCrossRef
64.
Simmons MJ, Serra R, Hermance N, Kelliher MA. NOTCH1 inhibition in vivo results in mammary tumor regression and reduced mammary tumorsphere-forming activity in vitro. Breast Cancer Res BCR. 2012;14:R126.PubMedCrossRef
65.
Bae Y-H, Ryu JH, Park H-J, Kim KR, Wee H-J, Lee O-H, et al. Mutant p53-Notch1 signaling Axis is involved in Curcumin-induced apoptosis of breast cancer cells. Korean J Physiol Pharmacol. 2013;17:291–7.PubMedPubMedCentralCrossRef
66.
Garimella SV, Gehlhaus K, Dine JL, Pitt JJ, Grandin M, Chakka S, et al. Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening. Breast Cancer Res. 2014;16:1–21.CrossRef
67.
Park S, Cho DH, Andera L, Suh N, Kim I. Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins. Mol Cell Biochem. 2013;383:39–48.PubMedCrossRef
68.
Rowe DL, Ozbay T, O’Regan RM, Nahta R. Modulation of the BRCA1 protein and induction of apoptosis in triple negative breast cancer cell lines by the Polyphenolic compound Curcumin. Breast Cancer Basic Clin Res. 2009;3:61–75.
69.
Singer C, Rasmussen A, Smith HS, Lippman ME, Lynch HT, Cullen KJ. Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function. Cancer Res. 1995;55:2448–54.PubMed
70.
Xia Y, Jin L, Zhang B, Xue H, Li Q, Xu Y. The potentiation of curcumin on insulin-like growth factor-1 action in MCF-7 human breast carcinoma cells. Life Sci. 2007;80:2161–9.PubMedCrossRef
71.
Banerjee M, Singh P, Panda D. Curcumin suppresses the dynamic instability of microtubules, activates the mitotic checkpoint and induces apoptosis in MCF-7 cells. FEBS J. 2010;277:3437–48.PubMedCrossRef
72.
73.
Nasiri M, Zarghami N, Koshki KN, Mollazadeh M, Moghaddam MP, Yamchi MR, et al. Curcumin and silibinin inhibit telomerase expression in T47D human breast cancer cells. Asian Pac J Cancer Prev. 2013;14:3449–53.PubMedCrossRef
74.
Hendrayani S-F, Al-Khalaf HH, Aboussekhra A. Curcumin triggers p16-dependent senescence in active breast cancer-associated fibroblasts and suppresses their Paracrine Procarcinogenic effects. Neoplasia. 2013;15:631–40.PubMedPubMedCentralCrossRef
75.
Weng D, Penzner JH, Song B, Koido S, Calderwood SK, Gong J. Metastasis is an early event in mouse mammary carcinomas and is associated with cells bearing stem cell markers. Breast Cancer Res. 2012;14:R18.PubMedPubMedCentralCrossRef
76.
Bimonte S, Barbieri A, Palma G, Rea D, Luciano A, D’Aiuto M, et al. Dissecting the role of Curcumin in tumour growth and angiogenesis in mouse model of human breast cancer. Biomed Res Int. 2015;2015 doi:10.​1155/​2015/​878134.
77.
Bachmeier B, Nerlich AG, Iancu CM, Cilli M, Schleicher E, Vené R, et al. The chemopreventive polyphenol Curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2007;19:137–52.CrossRef
78.
Bachmeier BE, Mohrenz IV, Mirisola V, Schleicher E, Romeo F, Höhneke C, et al. Curcumin downregulates the inflammatory cytokines CXCL1 and −2 in breast cancer cells via NFkappaB. Carcinogenesis. 2008;29:779–89.PubMedCrossRef
79.
Kim HI, Huang H, Cheepala S, Huang S, Chung J. Curcumin inhibition of Integrin (α6β4)-dependent breast cancer cell motility and invasion. Cancer Prev Res (Phila Pa). 2008;1:385–91.CrossRef
80.
Maass N, Hojo T, Zhang M, Sager R, Jonat W, Nagasaki K. Maspin--a novel protease inhibitor with tumor-suppressing activity in breast cancer. Acta Oncol Stockh Swed. 2000;39:931–4.CrossRef
81.
Prasad CP, Rath G, Mathur S, Bhatnagar D, Ralhan R. Expression analysis of maspin in invasive ductal carcinoma of breast and modulation of its expression by curcumin in breast cancer cell lines. Chem Biol Interact. 2010;183:455–61.PubMedCrossRef
82.
Sun K, Duan X, Cai H, Liu X, Yang Y, Li M, et al. Curcumin inhibits LPA-induced invasion by attenuating RhoA/ROCK/MMPs pathway in MCF7 breast cancer cells. Clin Exp Med. 2015;
83.
Kim J-M, Noh E-M, Kwon K-B, Kim J-S, You Y-O, Hwang J-K, et al. Curcumin suppresses the TPA-induced invasion through inhibition of PKCα-dependent MMP-expression in MCF-7 human breast cancer cells. Phytomedicine Int J Phytother Phytopharm. 2012;19:1085–92.CrossRef
84.
Zong H, Wang F, Fan Q-X, Wang L-X. Curcumin inhibits metastatic progression of breast cancer cell through suppression of urokinase-type plasminogen activator by NF-kappa B signaling pathways. Mol Biol Rep. 2012;39:4803–8.PubMedCrossRef
85.
Park H-J, Kim S-R, Kim SS, Wee H-J, Bae M-K, Ryu MH, et al. Visfatin promotes cell and tumor growth by upregulating Notch1 in breast cancer. Oncotarget. 2014;5:5087–99.PubMedPubMedCentralCrossRef
86.
Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer. 2007;14:189–206.PubMedCrossRef
87.
Kim S-R, Park H-J, Bae Y-H, Ahn S-C, Wee H-J, Yun I, et al. Curcumin down-regulates visfatin expression and inhibits breast cancer cell invasion. Endocrinology. 2012;153:554–63.PubMedCrossRef
88.
Ferreira LC, Arbab AS, Jardim-Perassi BV, Borin TF, Varma NR, Iskander A, et al. Effect of curcumin on pro-angiogenic factors in the xenograft model of breast cancer. Anticancer Agents Med Chem. 2015;15:1285–96.
89.
Chakraborty G, Jain S, Kale S, Raja R, Kumar S, Mishra R, et al. Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Mol Med Rep. 2008;1:641–6.PubMed
90.
Carroll CE, Ellersieck MR, Hyder SM. Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cells. Menopause. 2008;15:570–4.PubMedCrossRef
91.
Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008;68:152–61.PubMedCrossRef
92.
Creighton CJ, Chang JC, Rosen JM. Epithelial-Mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15:253–60.PubMedCrossRef
93.
Hardy KM, Booth BW, Hendrix MJC, Salomon DS, Strizzi L. ErbB/EGF signaling and EMT in mammary development and breast cancer. J Mammary Gland Biol Neoplasia. 2010;15:191–9.PubMedPubMedCentralCrossRef
94.
Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi J-P, Nevo J, Gjerdrum C, et al. Vimentin regulates EMT induction by slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011;30:1436–48.PubMedCrossRef
95.
Huang T, Chen Z, Fang L. Curcumin inhibits LPS-induced EMT through downregulation of NF-κB-snail signaling in breast cancer cells. Oncol Rep. 2013;29:117–24.PubMed
96.
Gallardo M, Calaf GM. Curcumin inhibits invasive capabilities through epithelial mesenchymal transition in breast cancer cell lines. Int J Oncol. 2016;49:1019–27.PubMed
97.
Onoda M, Inano H. Effect of curcumin on the production of nitric oxide by cultured rat mammary gland. Nitric Oxide Biol Chem Off J Nitric Oxide Soc. 2000;4:505–15.CrossRef
98.
Inano H, Onoda M, Inafuku N, Kubota M, Kamada Y, Osawa T, et al. Potent preventive action of curcumin on radiation-induced initiation of mammary tumorigenesis in rats. Carcinogenesis. 2000;21:1835–41.PubMedCrossRef
99.
Mauro C, Leow SC, Anso E, Rocha S, Thotakura AK, Tornatore L, et al. NF-κB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nat Cell Biol. 2011;13:1272–9.PubMedPubMedCentralCrossRef
100.
Lu J, Tan M, Cai Q. The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett. 2015;356:156–64.PubMedCrossRef
101.
Vaughan RA, Garcia-Smith R, Dorsey J, Griffith JK, Bisoffi M, Trujillo KA. Tumor necrosis factor alpha induces Warburg-like metabolism and is reversed by anti-inflammatory curcumin in breast epithelial cells. Int J Cancer. 2013;133:2504–10.PubMedCrossRef
102.
Chung SS, Vadgama JV. Curcumin and Epigallocatechin Gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3–NFκB signaling. Anticancer Res. 2015;35:39–46.PubMedPubMedCentral
103.
Charpentier MS, Whipple RA, Vitolo MI, Boggs AE, Slovic J, Thompson KN, et al. Curcumin targets breast cancer stem-like cells with microtentacles that persist in mammospheres and promote reattachment. Cancer Res. 2014;74:1250–60.PubMedCrossRef
104.
Kakarala M, Brenner DE, Khorkaya H, Cheng C, Tazi K, Ginestier C, et al. Targeting breast stem cells with the cancer preventive compounds Curcumin and Piperine. Breast Cancer Res Treat. 2010;122:777–85.PubMedCrossRef
105.
Colacino JA, McDermott SP, Sartor MA, Wicha MS, Rozek LS. Transcriptomic profiling of curcumin-treated human breast stem cells identifies a role for stearoyl-coa desaturase in breast cancer prevention. Breast Cancer Res Treat. 2016;158:29–41.PubMedCrossRef
106.
Mukherjee S, Mazumdar M, Chakraborty S, Manna A, Saha S, Khan P, et al. Curcumin inhibits breast cancer stem cell migration by amplifying the E-cadherin/β-catenin negative feedback loop. Stem Cell Res Ther. 2014;5:116.PubMedPubMedCentralCrossRef
107.
Casey SC, Amedei A, Aquilano K, Azmi AS, Benencia F, Bhakta D, et al. Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol. 2015;35(Suppl):S199–223.PubMedPubMedCentralCrossRef
108.
Zhang H-G, Kim H, Liu C, Yu S, Wang J, Grizzle WE, et al. Curcumin reverses breast tumor exosomes mediated immune suppression of NK cell tumor cytotoxicity. Biochim Biophys Acta. 2007;1773:1116–23.PubMedPubMedCentralCrossRef
109.
Iorio MV, Ferracin M, Liu C-G, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–70.PubMedCrossRef
110.
111.
Yang J, Cao Y, Sun J, Zhang Y. Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells. Med Oncol. 2010;27:1114–8.PubMedCrossRef
112.
Guo J, Li W, Shi H, Xie X, Li L, Tang H, et al. Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. Mol Cell Biochem. 2013;382:103–11.PubMedCrossRef
113.
Kronski E, Fiori ME, Barbieri O, Astigiano S, Mirisola V, Killian PH, et al. miR181b is induced by the chemopreventive polyphenol curcumin and inhibits breast cancer metastasis via down-regulation of the inflammatory cytokines CXCL1 and −2. Mol Oncol. 2014;8:581–95.PubMedCrossRef
114.
Li X, Xie W, Xie C, Huang C, Zhu J, Liang Z, et al. Curcumin modulates miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7 breast cancer cell proliferation. Phytother Res. 2014;28:1553–60.PubMedCrossRef
115.
Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: a review. Int J Cancer. 2016;138:2570–8.PubMedCrossRef
116.
Zhang X, Tian W, Cai X, Wang X, Dang W, Tang H, et al. Hydrazinocurcumin Encapsuled nanoparticles “re-educate” tumor-associated macrophages and exhibit anti-tumor effects on breast cancer following STAT3 suppression. PLoS One. 2013;8:e65896.PubMedPubMedCentralCrossRef
117.
Hutzen B, Friedman L, Sobo M, Lin L, Cen L, De Angelis S, et al. Curcumin analogue GO-Y030 inhibits STAT3 activity and cell growth in breast and pancreatic carcinomas. Int J Oncol. 2009;35:867–72.PubMed
Metadata
Title
Curcumin: the spicy modulator of breast carcinogenesis
Authors
Urmila Banik
Subramani Parasuraman
Arun Kumar Adhikary
Nor Hayati Othman
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2017
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-017-0566-5

Other articles of this Issue 1/2017

Journal of Experimental & Clinical Cancer Research 1/2017 Go to the issue

Research

LncRNA AK023391 promotes tumorigenesis and invasion of gastric cancer through activation of the PI3K/Akt signaling pathway

Research

HERV-K activation is strictly required to sustain CD133+ melanoma cells with stemness features

Research

ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway

Review

Type II CRISPR/Cas9 approach in the oncological therapy

Research

E2F8, a direct target of miR-144, promotes papillary thyroid cancer progression via regulating cell cycle

Erratum

Erratum to: Pathologically decreased expression of miR-193a contributes to metastasis by targeting WT1-E-cadherin axis in non-small cell lung cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits